A microarray is a multiplex lab-on-a-chip. It is a 2D array on a solid substrate, usually a glass slide or silicon thin-film cell, that assays large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods.
The concept and methodology of microarrays was first introduced and illustrated in antibody microarrays in 1983. With the establishment of companies, such as Affymetrix, Agilent, Applied Microarrays, Arrayit, Illumina, and others, the technology of DNA microarrays has become the most sophisticated and the most widely used. DNA microarrays are microscope slides that are printed with thousands of tiny spots in defined positions, with each spot containing a known DNA sequence or gene. Often, these slides are referred to as gene chips or DNA chips. The DNA molecules attached to each slide act as probes to detect gene expression, which is also known as the transcriptome or the set of messenger RNA (mRNA) transcripts expressed by a group of genes.
Globally the microarray market is dominated by DNA microarrays. The protein microarray is currently the fastest growing market. The use of peptide and carbohydrate microarrays is expanding. Tissue and cell microarrays are in their infancy stage and are developing slowly because of many complications in the process development
Further In the coming years, the global microarray market will advance more than it has in the past several years. DNA microarray is holding the large market share in the microarray industry. Initially it may take time for widespread growth of types like tissue and cellular microarray. But in the near future, as the research in this field progresses, tissue microarray will play an integral part in the diagnostic techniques in the field of cancer research and diagnosis.
Get a Copy of Sample Report @ https://www.marketresearchfuture.com/sample_request/777 .
Tissue microarray is relatively new technique and a lot of research in tissue microarray is still going on. As the technique is in its infancy stage, lots of inaccuracies and errors occur. The readings are not accurate in most of the analysis. As the results are not reliable, it creates a hindrance in the growth of the tissue microarray method.
Besides this, microarrays are not recommended for certain types of studies. In certain tumours such as glioblastoma, there is such marked heterogeneity within tumours that this feature may not be adequately captured in microarray studies.
In addition, microarray analysis is not very useful to study rare or focal events, such as number of immune cells in tumours. It is difficult to study certain facets of tumour biology, such as interactions between the tumour and its stroma, as these stromal components may not be adequately represented in the cores.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/global-microarray-analysis-market-777 .
Global Microarray Analysis Market – Competitive Analysis
Abcam, Asterand Bioscience, IHC World, LLC, Novus Biologicals Llc (Acquired By Bio-Techne), Origene Technologies, Inc, Pantomics, Inc, Protein Biotechnologies Inc, US Biomax, Inc, Agilent Technologies, Illumina, Thermo Fisher Scientific, Merck are some of the prominent players at the forefront of competition in the Global Microarray Analysis Market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small players, the global Market of Microarray Analysis seems to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The Market is witnessing strengthened competition which is anticipated to be more intensified further during the forecast period. The intense competition predominant in the market dictates the alliance and associations among marketers.
Well established and emerging players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Dated: June 2017, Agendia proclaimed a contract extension of its association with Agilent Technologies Inc. to develop an RNA sequencing-based version of its prevailing microarray-based MammaPrint and BluePrint tests. As a result of this contract extension the MammaPrint BluePrint Kit of Agendia’s portfolio will empower cancer centers to run the tests on their prevailing next-generation sequencing (NGS) instruments in their own laboratories. Thus performing the test locally bids superior access so that more patients can take advantage from the personalized treatment that these tests are capable of. Further the study will include UZ Leuven processing breast tumour samples from patients registered in the study using the NGS-based MammaPrint BluePrint Kit. The results of these patients will be directly associated with those from the presently marketed MammaPrint microarray-based test, executed at the Company’s Amsterdam CLIA-certified and CAP-accredited laboratory, to validate the comparability of the two technologies.
Get Discount @ https://www.marketresearchfuture.com/check-discount/777 .
We are thankful for the support and assistance from Microarray Analysis Market Research Report- Global Forecast to 2027 chain related technical experts and marketing experts during Research Team survey and interviews.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –